Published in J Clin Densitom on January 01, 2005
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int (2008) 1.68
Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation. Menopause (2012) 1.66
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Reproducibility of DXA measurements of bone mineral density and body composition in children. Pediatr Radiol (2008) 1.22
An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr (2010) 1.02
Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes. Proc Natl Acad Sci U S A (2012) 0.97
BMD measurement and precision: a comparison of GE Lunar Prodigy and iDXA densitometers. J Clin Densitom (2011) 0.94
Osteoporosis care at risk in the United States. Osteoporos Int (2008) 0.91
Reliability of clinically relevant 3D foot bone angles from quantitative computed tomography. J Foot Ankle Res (2013) 0.90
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.88
Navel jewelry artifacts and intravertebral variation in spine bone densitometry in adolescents and young women. J Clin Densitom (2008) 0.86
Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study. J Bone Miner Metab (2014) 0.86
Exercise training in childhood-onset systemic lupus erythematosus: a controlled randomized trial. Arthritis Res Ther (2013) 0.84
Alveolar bone measurement precision for phosphor-plate images. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 0.82
Differences in precision in bone mineral density measured by SXA and DXA: the NOREPOS study. Eur J Epidemiol (2008) 0.82
Reproducibility of a peripheral quantitative computed tomography scan protocol to measure the material properties of the second metatarsal. BMC Musculoskelet Disord (2014) 0.80
Lean mass asymmetry influences force and power asymmetry during jumping in collegiate athletes. J Strength Cond Res (2014) 0.79
Racial difference in the correlates of bone mineral content/density and age at peak among reproductive-aged women. Osteoporos Int (2009) 0.78
Adherence to raloxifene therapy: assessment methods and relationship with efficacy. Osteoporos Int (2013) 0.78
Peripheral Quantitative Computed Tomography Predicts Humeral Diaphysis Torsional Mechanical Properties With Good Short-Term Precision. J Clin Densitom (2014) 0.78
Fragility fracture: recent developments in risk assessment. Ther Adv Musculoskelet Dis (2015) 0.78
Monitoring time interval for pQCT-derived bone outcomes in postmenopausal women. Osteoporos Int (2013) 0.78
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. Cancer Prev Res (Phila) (2016) 0.77
Contribution of fat-free mass and fat mass to bone mineral density among reproductive-aged women of white, black, and Hispanic race/ethnicity. J Clin Densitom (2009) 0.77
Chronic effects of stroke on hip bone density and tibial morphology: a longitudinal study. Osteoporos Int (2015) 0.76
Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy. Support Care Cancer (2013) 0.76
Changes in Nonosteoporotic Bone Density and Subsequent Fractures in Women. South Med J (2016) 0.76
The Prevalence of Undetected Vertebral Fracture in Patients with Back Pain by Dual-Energy X-ray Absorptiometry (DXA) of the Lateral Thoracic and Lumbar Spine. Asian Spine J (2011) 0.76
Feasibility study of emergency intervention for vascular injury outside the hospital. Mil Med Res (2016) 0.75
Efficacy of home-based virtual cycling training on bone mineral density in ambulatory children with cerebral palsy. Osteoporos Int (2012) 0.75
Should all elderly women receive bisphosphonates to prevent osteoporotic fractures? Can J Hosp Pharm (2012) 0.75
Protecting Skeletal Muscle with Protein and Amino Acid during Periods of Disuse. Nutrients (2016) 0.75
Precision of dual-energy X-ray absorptiometry of the knee and heel: methodology and implications for research to reduce bone mineral loss after spinal cord injury. Spinal Cord (2016) 0.75
Dual-energy X-ray absorptiometry of human metatarsals: precision, least significant change and association to ex vivo fracture force. Foot (Edinb) (2013) 0.75
Modulation and predictors of periprosthetic bone mineral density following total knee arthroplasty. Biomed Res Int (2015) 0.75
Osteoporosis Imaging in the Geriatric Patient. Curr Radiol Rep (2016) 0.75
Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents. J Bone Metab (2016) 0.75
A rose by any other name, or when is research not research? J Clin Densitom (2006) 0.75
Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. PLoS One (2017) 0.75
[Antiosteoporosis medication: useful monitoring, and how long should such treatment be continued?]. Z Rheumatol (2006) 0.75
Optimal decision criterion for detecting change in bone mineral density during serial monitoring: a Bayesian approach. Osteoporos Int (2008) 0.75
Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia. Osteoporos Int (2016) 0.75
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Official positions of the International Society for Clinical Densitometry. J Clin Densitom (2004) 3.63
Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 3.11
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom (2008) 2.21
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab (2004) 1.96
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Report of a summit on molecular imaging. Radiology (2005) 1.79
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res (2012) 1.77
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom (2008) 1.76
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res (2005) 1.68
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.66
Goal-directed treatment of osteoporosis. J Bone Miner Res (2013) 1.58
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause (2013) 1.47
Algorithm for the management of osteoporosis. South Med J (2010) 1.45
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.41
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.35
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res (2008) 1.32
Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther (2002) 1.27
Effects of gastric bypass procedures on bone mineral density, calcium, parathyroid hormone, and vitamin D. J Gastrointest Surg (2005) 1.27
Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.26
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Vertebral fracture assessment: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.21
Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom (2004) 1.18
The long-term effects of gastric bypass on vitamin D metabolism. Ann Surg (2006) 1.16
Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom (2007) 1.15
FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom (2011) 1.12
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab (2010) 1.12
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Position, position. Radiology (2014) 1.07
Efficacy and safety of monthly ibandronate in men with low bone density. Bone (2010) 1.04
Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom (2006) 1.03
Prevalence of the female athlete triad in high school athletes and sedentary students. Clin J Sport Med (2009) 1.03
Safety of bisphosphonates in the treatment of osteoporosis. Am J Med (2009) 1.02
Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin (2005) 1.01
A 1-year study of osteoinduction in hydroxyapatite-derived biomaterials in an adult sheep model: part I. Plast Reconstr Surg (2002) 1.00
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom (2011) 1.00
Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res (2004) 1.00
Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab (2013) 0.98
Skeletal health in long-duration astronauts: nature, assessment, and management recommendations from the NASA Bone Summit. J Bone Miner Res (2013) 0.98
Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 0.94
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone (2006) 0.94
Secular trends in hip fractures worldwide: opposing trends East versus West. J Bone Miner Res (2014) 0.93
Is it ethical to use placebos in osteoporosis trials? J Clin Densitom (2006) 0.91
Is there an association between athletic amenorrhea and endothelial cell dysfunction? Med Sci Sports Exerc (2003) 0.91
Standards for performing DXA in individuals with secondary causes of osteoporosis. J Clin Densitom (2006) 0.91
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab (2007) 0.89
Summary of the International Society For Clinical Densitometry 2005 Position Development Conference. J Bone Miner Res (2007) 0.89
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Official positions of the International Society for Clinical Densitometry. Osteoporos Int (2006) 0.88
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom (2008) 0.88
Report of a summit on molecular imaging. AJR Am J Roentgenol (2006) 0.86
Official positions of the International Society for Clinical Densitometry. South Med J (2004) 0.85
Update on romosozumab : a humanized monoclonal antibody to sclerostin. Expert Opin Biol Ther (2014) 0.84
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab (2015) 0.84
In the clinic. Osteoporosis. Ann Intern Med (2011) 0.84
A 1-year study of hydroxyapatite-derived biomaterials in an adult sheep model: III. Comparison with autogenous bone graft for facial augmentation. Plast Reconstr Surg (2005) 0.82
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
International Society for Clinical Densitometry official positions: Asia-Pacific Region consensus. J Clin Densitom (2010) 0.82
Position Development Conference of the International Society for Clinical Densitometry. Vancouver, BC, July 15-17, 2005. J Rheumatol (2006) 0.81
Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med (2006) 0.81
Fracture risk prediction: importance of age, BMD and spine fracture status. Bonekey Rep (2013) 0.81
Joint SNM/RSNA Molecular Imaging Summit Statement. J Nucl Med (2005) 0.81
A 1-year study of osteoinduction in hydroxyapatite-derived biomaterials in an adult sheep model: part II. Bioengineering implants to optimize bone replacement in reconstruction of cranial defects. Plast Reconstr Surg (2004) 0.81
Vertebral Fracture Assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A White Paper of the International Society for Clinical Densitometry. J Clin Densitom (2007) 0.80
Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol (2015) 0.80
A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome. Trans Am Clin Climatol Assoc (2012) 0.79
Opacification of the genitourinary collecting system during MDCT urography with enhanced CT digital radiography: nonsaline versus saline bolus. AJR Am J Roentgenol (2006) 0.79
The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. Curr Opin Nephrol Hypertens (2015) 0.78
Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Ther Adv Musculoskelet Dis (2009) 0.78
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother (2005) 0.78
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. Endocr Pract (2016) 0.77
Diagnostic agreement at the total hip using different DXA systems and the NHANES III database. J Clin Densitom (2007) 0.77
Standards and guidelines for technologists performing central dual-energy X-ray absorptiometry. J Clin Densitom (2007) 0.77
Augmentation procedures for osteoporotic vertebral fractures--an ongoing experiment or emerging standard of care? South Med J (2006) 0.77
Bone-density testing interval and transition to osteoporosis. N Engl J Med (2012) 0.77
RSNA Board restructures cabinet to strengthen support of radiologic science and research. Radiology (2003) 0.77
Impact of using the ultradistal radius region of interest on diagnostic classification. J Clin Densitom (2004) 0.77
Comparison of canine mandibular bone regeneration by distraction osteogenesis versus acute resection and rigid external fixation. Plast Reconstr Surg (2004) 0.77
An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care (2007) 0.77
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. Endocr Pract (2016) 0.77
Proceedings of the 5th annual perspectives in rheumatic diseases. Semin Arthritis Rheum (2013) 0.76
Peripheral bone densitometry: Clinical applications. Arq Bras Endocrinol Metabol (2006) 0.76
The evolution of fracture risk estimation. J Bone Miner Res (2010) 0.76
A review of strontium ranelate and its effect on DXA scans. J Clin Densitom (2007) 0.76
Sclerostin and skeletal health. Rev Endocr Metab Disord (2015) 0.76